Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.58 |
| ▸ | PNLIP | P16233 | 3/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16622816 | 0.86 | POLB (0.81) | POLBMAPTPTPN1PNLIPPTPN2 | |
| SCHEMBL31347993 | 0.85 | POLB (1.00) | POLBMAPTPTPN1PNLIPPTPN2 | |
| SCHEMBL31571682 | 0.85 | POLB (1.00) | POLBMAPTPTPN1PNLIPPTPN2 | |
| SCHEMBL14769472 | 0.85 | POLB (1.00) | POLBMAPTPTPN1PNLIPPTPN2 | |
| SCHEMBL28790287 | 0.85 | POLB (1.00) | POLBMAPTPTPN1PNLIPPTPN2 | |
| SCHEMBL16622804 | 0.85 | POLB (1.00) | POLBMAPTPTPN1PNLIPPTPN2 | |
| SCHEMBL2406902 | 0.85 | POLB (1.00) | POLBMAPTPTPN1PNLIPPTPN2 | |
| Isocupressic Acid SCHEMBL19139984 | 0.78 | POLB (0.66) | POLBMAPTPTPN1PNLIPPTPN2 | |
| Isocupressic Acid SCHEMBL13532265 | 0.78 | POLB (0.66) | POLBMAPTPTPN1PNLIPPTPN2 | |
| SCHEMBL23015444 | 0.76 | MAPT (0.60) | POLBMAPTPTPN1PNLIPPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857391-B1 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF | UNIV SUN YAT SEN (CN) | 2017-07-19 | — | — | EP | disclosed |
| US-9682111-B2 | Method for preventing or treating neurodegenerative diseases | SU WEIWEI (CN) | 2017-06-20 | — | — | US | disclosed |
| US-20160082059-A1 | METHOD FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | SU WEIWEI (CN) | 2016-03-24 | — | — | US | disclosed |
| US-20150105460-A1 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF | SU WEIWEI (CN) | 2015-04-16 | — | — | US | disclosed |
| EP-2857391-A1 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF | Sun Yat-Sen University (CN) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105460-A1 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF | NASP, GSDMD, DRD5 | POLB 1492/4885MAPT 139/4885PTPN1 4881/4885 |
| US-20160082059-A1 | METHOD FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | POLB 708/4885MAPT 9/4885PTPN1 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.